Scinai Immunotherapeutics (SCNI) CEO receives 400,000,000-share RSU award

Rhea-AI Filing Summary

Reichman Amir reported acquisition or exercise transactions in this Form 4 filing.

Scinai Immunotherapeutics Ltd. reported that Chief Executive Officer Amir Reichman received a grant of 400,000,000 Ordinary Shares on June 16, 2026 as a stock award. The shares were granted at a per-share price of $0.00 and are represented by restricted share units (RSUs).

The 400,000,000 Ordinary Shares vest in three equal annual installments after the grant date, subject to his continued service. After this award, Reichman directly owns 711,637,600 Ordinary Shares, including RSUs granted on January 25, 2024 and December 22, 2025, each with its own multi-year vesting schedule. Each American Depositary Share currently represents 4,000 Ordinary Shares.

Insights

Equity compensation analyst

CEO receives large multi-year RSU grant, increasing unvested equity exposure.

The filing shows Amir Reichman, CEO of Scinai Immunotherapeutics Ltd., was awarded 400,000,000 Ordinary Shares as RSUs on June 16, 2026 at $0.00 per share. This is a non-cash, compensation-related acquisition rather than an open-market purchase.

The RSUs vest in three equal annual installments after the grant date, so actual share delivery depends on continued service. Existing RSU grants from January 25, 2024 and December 22, 2025 add to his future equity exposure. Overall, this is a routine executive equity award with neutral standalone impact.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Reichman Amir

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	400,000,000	$0.00	--

Holdings After Transaction: Ordinary Shares — 711,637,600 shares (Direct, null)

Footnotes (1)

1. The Ordinary Shares are no par value per share, and are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares. Includes 400,000,000 Ordinary Shares represented by restricted share units ("RSUs") granted on June 16, 2026, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. Includes 71,637,600 Ordinary Shares represented by RSUs granted on January 25, 2024, of which 25% vested on the six-month anniversary thereof, 8.33% vested on the one-year anniversary thereof, and 66.66% vest in two equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. Each RSU represents a contingent right to receive one Ordinary Share upon vesting. Includes 240,000,000 Ordinary Shares represented by RSUs granted on December 22, 2025, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates.

Key Figures

RSU grant size: 400,000,000 Ordinary Shares Grant price: $0.00 per share Post-grant holdings: 711,637,600 Ordinary Shares +3 more

6 metrics

RSU grant size 400,000,000 Ordinary Shares RSUs granted to CEO on June 16, 2026

Grant price $0.00 per share Price for June 16, 2026 RSU grant

Post-grant holdings 711,637,600 Ordinary Shares Direct holdings following transaction

ADS ratio 1 ADS = 4,000 Ordinary Shares Representation of Ordinary Shares by ADS

Jan 25, 2024 RSUs 71,637,600 Ordinary Shares RSUs with staged vesting over multiple years

Dec 22, 2025 RSUs 240,000,000 Ordinary Shares RSUs vesting in three equal annual installments

Key Terms

restricted share units ("RSUs"), American Depositary Shares, Ordinary Shares, vesting, +1 more

5 terms

restricted share units ("RSUs") financial

"Includes 400,000,000 Ordinary Shares represented by restricted share units ("RSUs") granted on June 16, 2026"

American Depositary Shares financial

"are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Ordinary Shares financial

"The Ordinary Shares are no par value per share, and are represented by American Depositary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

vesting financial

"which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

contingent right financial

"Each RSU represents a contingent right to receive one Ordinary Share upon vesting"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/18/2026 - 02:50 PM Accepted by SEC EDGAR 06/18/2026 - 02:48 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reichman Amir

(Last) (First) (Middle)

C/O SCINAI IMMUNOTHERAPEUTICS LTD.

JERUSALEM BIOPARK, 2ND FLOOR

(Street)

JERUSALEM 9112002

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Scinai Immunotherapeutics Ltd. [ SCNI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/16/2026		A		400,000,000(2)	A	$0	711,637,600(3)(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares are no par value per share, and are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares.

2. Includes 400,000,000 Ordinary Shares represented by restricted share units ("RSUs") granted on June 16, 2026, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates.

3. Includes 71,637,600 Ordinary Shares represented by RSUs granted on January 25, 2024, of which 25% vested on the six-month anniversary thereof, 8.33% vested on the one-year anniversary thereof, and 66.66% vest in two equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. Each RSU represents a contingent right to receive one Ordinary Share upon vesting.

4. Includes 240,000,000 Ordinary Shares represented by RSUs granted on December 22, 2025, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates.

	/s/ Amir Reichman	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Scinai Immunotherapeutics (SCNI) CEO Amir Reichman receive in this Form 4?

Amir Reichman received a grant of 400,000,000 Ordinary Shares as restricted share units on June 16, 2026 at $0.00 per share. The award is equity compensation, not an open-market purchase, and increases his future share-based interest in the company.

How do the CEO’s new RSUs at Scinai Immunotherapeutics (SCNI) vest?

The 400,000,000 Ordinary Shares granted as RSUs on June 16, 2026 vest in three equal annual installments after the grant date. Vesting is conditioned on Amir Reichman’s continued service with Scinai Immunotherapeutics through each applicable vesting date.

What are Amir Reichman’s total Ordinary Share holdings after this Scinai (SCNI) award?

Following the June 16, 2026 grant, Amir Reichman directly holds 711,637,600 Ordinary Shares. This total includes the new 400,000,000-share RSU grant and prior RSU grants from January 25, 2024 and December 22, 2025 with their own vesting schedules.

Are Scinai Immunotherapeutics (SCNI) American Depositary Shares affected by this Form 4?

The filing notes that the company’s Ordinary Shares are represented by American Depositary Shares, with each ADS currently representing 4,000 Ordinary Shares. The Form 4 itself records the CEO’s RSU-based Ordinary Share holdings, which correspond to these ADS units.

What prior RSU grants to the Scinai (SCNI) CEO are referenced?

The filing references 71,637,600 Ordinary Shares from RSUs granted on January 25, 2024 and 240,000,000 Ordinary Shares from RSUs granted on December 22, 2025. These earlier grants have multi-step vesting schedules tied to specific anniversaries and continued service conditions.